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Peroxiredoxins (Prxs) are ubiquitous thiol peroxidases that are involved in the reduction of peroxides. It has been reported that
prokaryotic Prxs generally show greater structural robustness than their eukaryotic counterparts, making them less prone to
inactivation by overoxidation. This difference has inspired the search for new antioxidants from prokaryotic sources that can be
used as possible therapeutic biodrugs. Bacterioferritin comigratory proteins (Bcps) of the hyperthermophilic archaeon Sulfolobus
solfataricus that belong to the Prx family have recently been characterized. One of these proteins, Bcp1, was chosen to determine
its antioxidant effects in H9c2 rat cardiomyoblast cells. Bcp1 activity was measured in vitro under physiological temperature and
pH conditions that are typical of mammalian cells; the yeast thioredoxin reductase (yTrxR)/thioredoxin (yTrx) reducing system
was used to evaluate enzyme activity. A TAT-Bcp1 fusion protein was constructed to allow its internalization and verify the effect
of Bcp1 on H9c2 rat cardiomyoblasts subjected to oxidative stress. The results reveal that TAT-Bcp1 is not cytotoxic and inhibits
H
2
O
2
-induced apoptosis in H9c2 cells by reducing the H
2
O
2
content inside these cells.
1. Introduction
Reactive oxygen species (ROS), notably, superoxide (O
2
∙−),
the hydroxyl radical (HO∙), and hydrogen peroxide (H
2
O
2
),
are potent oxidants that are generated during aerobic
metabolism and in response to external factors. At high con-
centrations, ROS can damage all major classes of biological
macromolecules, leading to protein oxidation, lipid peroxida-
tion, DNAbasemodifications, and strand breaks. In addition,
H
2
O
2
plays a key role in cellular metabolism because it
functions as a signalling molecule that regulates cell growth,
cell adhesion, cell differentiation, and apoptosis. For these
reasons, the ROS concentrations must be strictly controlled.
However, the regulation of the ROS concentrations within
cells is not clearly understood [1].
Living organisms have evolved different antioxidant
defence systems to protect themselves against ROS toxic-
ity. Among the antioxidant enzymes, superoxide dismutase
(SOD) is involved in the dismutation reaction of O
2
∙− in
H
2
O
2
that in turn is converted to H
2
O by an array of
enzymes, such as catalase, glutathione peroxidase (GPx), and
peroxiredoxin (Prx). Recently, attention has been given to
Prxs, which are ubiquitous thiol peroxidases in archaea and
eukaryotes, including humans. All Prxs share a common
structure characterized by the thioredoxin (Trx) fold [2]. Prxs
are typically classified as either 1-Cys Prxs or 2-Cys Prxs,
depending upon the cysteine residues involved in catalysis.
In 2-Cys Prxs, the first cysteine is located at the N-terminus
and it is known as peroxidatic cysteine (CP), whereas the
second cysteine is called the resolving cysteine (CR). The CR
is situated at the C-terminus or in different central positions
downstream of CP [3, 4]. H2O2 oxidizes CP to sulfenic acid
(CP-SOH), which in turn condenses with CR to form a disul-
fide bond. A disulfide reducing system, generally composed
of thioredoxin reductase (TrxR)/thioredoxin (Trx), is coupled
to Prx for recycling [5]. In some Prxs, called sensitive Prxs,
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H
2
O
2
can further oxidize CP-SOH to its inactive forms, the
sulfinic (CP-SO2H) or sulfonic (CP-SO3H) acids, thereby
preventing disulfide bond formation and inactivating the
enzyme. The reason for this sensitivity is due to specific
structural motifs. Specifically, a “GGLG” sequence and a YF
C-terminal extension stiffen and stabilize the fully folded (FF)
active site, making the enzyme more susceptible to overox-
idation [6–8]. For this reason, eukaryotic Prxs are termed
sensitive in contrast to the large majority of prokaryotic Prxs,
which are considered robust because they lack these motifs
[9]. This structural feature acquired during the evolution
endows sensitive Prxs with additional functionality beyond
basic antioxidant activity, including the ability to regulate
peroxide signalling in eukaryotic cells [10].
An array of bacterioferritin comigratory proteins (Bcps)
belonging to Prx family, named Bcp1, Bcp2, Bcp3, and Bcp4,
have been recently characterized from the hyperthermophilic
archaeon Sulfolobus solfataricus [2, 11–13]. Archaeal Bcp1 was
expressed in E. coli and characterized [4]. It is reported
that Bcp1 regenerates through an unusual coupling mecha-
nism. Specifically, a reduction mediated by the interaction
of SsTrxR (Sso2416) and Protein Disulfide Oxidoreductase
(SsPDO) (Sso0192) [14–16] replaces the standard Trx. Func-
tional studies reveal that Bcp1 performs the catalytic reaction
using an atypical 2-Cys mechanism, in which CP45 forms an
intramolecular disulfide bondwithCR50.TheX-ray structure
of the C45S/C50S double mutant, which represents the fully
reduced enzyme state, was determined to a resolution of
2.15 A˚ and showed a Trx fold that was similar to other Prxs
[4].
This paper shows that archaeal Prx can function as
an antioxidant in eukaryotic cells. Specifically, our data
show Bcp1 peroxidase activity under pH and temperature
conditions that are typical of mammalian cells. Furthermore,
we show that the archaeal Prx is active, although eukaryotic
recycling system (different from that of Sulfolobus) is used
[14]. A fusion protein consisting of HIV Transactivating
Transduction (TAT) peptide [17] and Bcp1 was constructed to
facilitate uptake into H9c2 cells. Its possible cytotoxic effects
and ability to decrease the H
2
O
2
levels inside the cells were
also evaluated. Our results indicate that in an in vitro cellular
system (i.e., H9c2 rat cardiomyoblasts), the archaeal enzyme
can (1) function as an antioxidant to reduce the endogenous
peroxide levels and (2) decrease cellular apoptosis following
H
2
O
2
-induced stress.
2. Materials and Methods
2.1. Expression and Purification of Recombinant Proteins
in E. coli
2.1.1. Bcp1 from S. solfataricus. Escherichia coli BL21-Codon-
Plus (DE3)RIL/pETBcp1 [12] was grown to OD
600 nm of 0.8 in
Luria-Bertani (LB) medium supplemented with kanamycin
(10 𝜇gmL−1) and chloramphenicol (34 𝜇gmL−1) at 37∘C.
Bcp1 expression was induced with 1mM isopropyl-𝛽-D-
thiogalactoside (IPTG) (Inalco) for 6 h at 37∘C. E. coli
cells containing the recombinant protein were harvested by
centrifugation, and the pellet from a 1 L culture was sus-
pended in 20mL of ice-cold 20mM Tris-HCl, pH 8.0,
containing a complete EDTA-free protease inhibitor cocktail
(Roche, IN,USA).Theproteinwas purified using a previously
described method [11].
2.1.2. Thioredoxin (yTrx) and Thioredoxin Reductase (yTrxR)
from Yeast. E. coli BL21-CodonPlus (DE3)RIL was trans-
formedwith pET17yTrx or pET17yTrxR [18] (both generously
provided by SangWon Kang, University of Seoul, Korea) and
cultured in 1 L of LB medium supplemented with ampicillin
(100 𝜇gmL−1) and chloramphenicol (34 𝜇gmL−1) at 37∘C.
The expression of both yTrx and yTrxR was induced with
0.5mM IPTG for 16 h at 37∘C to an OD
600 nm of 0.8. The E.
coli cells were harvested by centrifugation and each pellet
was suspended in 20mL of ice-cold 20mM Tris-HCl, pH
7.5, 10mM NaCl, 5mM DTT, 1mM EDTA, and a complete
EDTA-free protease inhibitor cocktail and disrupted by
sonication with 5min pulses at 20Hz (30󸀠󸀠 on and 30󸀠󸀠 off).
The soluble fractions were obtained after ultracentrifugation
at 160,000×g for 30min at 4∘C.
The cell extract was heated at 75∘C for 30min, centrifuged
at 15,000×g at 4∘C for 30min, and then concentrated (Ami-
con, Millipore Corp., Bedford, MA, USA) to purify yTrx.The
sample was loaded on a Superdex S-75 column (30 cm × 1 cm,
25mL) that had been equilibrated with 50mM Tris-HCl, pH
7.5, and 0.2M KCl and was connected to an AKTA system
(GE Healthcare). The elution was performed at a flow rate of
0.4mLmin−1.
The sample was loaded onto a Hi-Trap DEAE FF column
(7 × 25mm, 1mL) in 20mM Tris-HCl, pH 7.5, and 1mM
EDTA connected to AKTA system (GE Healthcare) to purify
yTrxR. The proteins were eluted with a linear gradient of 0–
0.5M NaCl in 30min at a flow rate of 0.5mLmin−1.
For both proteins, the fractions were pooled, analysed
by SDS-PAGE, and extensively dialysed against 20mM Tris-
HCl, pH 7.0.
2.2. Enzymatic Activities
2.2.1. yTrx and yTrxR Activity Assays. yTrx activity was de-
tected using the insulin precipitation assay [19], in a reaction
mixture containing 0.1M sodium phosphate pH 7.0, 2mM
EDTA, 1mgmL−1 insulin, 1mM DTT, and 5 𝜇M yTrx. The
increase in the absorbance due to the precipitation of the
insulin B chain was monitored at 650 nm in a Varian Cary
50 Bio UV-Vis spectrophotometer.
yTrxR activity was evaluated using the 5,5󸀠-dithiobis(2-
nitrobenzoic acid) (DTNB) reduction method [20]. The for-
mation of the 2-nitro-5-thiobenzoate product was monitored
spectrophotometrically by the increase at𝐴
412nm at 30
∘C.The
reaction mixture contained 0.1M potassium phosphate, pH
7.0, 2mM EDTA, 0.2mM NADPH, 0.05mM FAD, 0.5mM
DTNB, and 0.2 𝜇M yTrxR.
2.2.2. Bcp1 Activity Assays. Bcp1 peroxidase activity was test-
ed in an assay usingDTT [11].The reactionmixture contained
0.1M Hepes, pH 7.0, 10mM DTT, 0.1mM H
2
O
2
, and 10 𝜇M
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Bcp1. After incubation for 5min at 37∘C, the reaction was
stopped adding a trichloroacetic acid solution (10%w/v).
The amount of H
2
O
2
remaining was detected by measuring
the 𝐴
490 nm of the purple-coloured ferrothiocyanate com-
plex that developed after the addition of 0.2mL of 10mM
Fe(NH
4
)
2
(SO
4
)
2
and 0.1mL of 2.5M KSCN.
The effect of pH on Bcp1 activity was analysed using
0.1M citrate phosphate (pH 5.5–6.5) and 0.1M Hepes (pH
7.0–7.5) buffers and the assay conditions reported above. The
pH stability of Bcp1 was also evaluated after the enzyme was
incubated in the buffers (pH 5.5–7.0) for 30min, 1 h, 2 h, 4 h,
and 16 h, and the residual peroxidase activity was determined
under standard conditions.
The peroxidase activity was also evaluated using
NADPH/yTrxR/yTrx as the electron donor system to reduce
Bcp1. The assay mixture contained 50mM Hepes, pH 7.0,
1mM EDTA, 0.2mM NADPH, 5–100𝜇M yTrx, 0.1 𝜇M
yTrxR, and 3.5 𝜇M Bcp1. After preincubation at 30∘C for
2min, the reaction was started by adding 0.2mMH
2
O
2
. The
NADPH oxidation was monitored spectrophotometrically at
340 nm.
2.3. TAT-Bcp1: Cloning, Expression, andPurification. The bcp1
coding sequence was isolated from the pET30Bcp1 vector
[12] after digestion with the NdeI and XhoI restriction
endonucleases. The bcp1 fragment was purified by agarose
gel electrophoresis using the QIAquick Gel Extraction Kit
(Qiagen, Milano, Italy) and cloned into the pTAT2.2 expres-
sion vector (Addgene, Cambridge, USA). E. coli BL21-
CodonPlus (DE3)RIL competent cells were transformed with
the obtained vector, pTAT2.2-Bcp1, and selected on LB agar
plates with kanamycin (10 𝜇gmL−1) and chloramphenicol
(34 𝜇gmL−1).The selected colonywas cultured in LBmedium
with the same antibiotics at 37∘C. The cells were grown
up to an OD
600 nm of 0.8 and the expression of TAT-Bcp1
was induced with 1mM IPTG for 3 h at 37∘C. TAT-Bcp1
was purified using the same conditions described for Bcp1.
Peroxidase activity was evaluated using the DTT assay at
37∘C, as reported for Bcp1.
2.4. Cell Culture and Treatment. H9c2 cells (Rat Embryonic
Myocardium Cells, CRL-1446) were purchased from the
American Type Culture Collection (ATCC) and grown in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% foetal bovine serum (FBS), 4mM L-glutamine,
a 1% v/v penicillin/streptomycin solution (100UmL−1), and
1mM sodium pyruvate (Euroclone,Milano, Italy) at 37∘C in a
5% CO
2
incubator. A freshly prepared H
2
O
2
(Sigma-Aldrich,
Milano, Italy) stock aqueous solution was added to the cells
at a final concentration of 0.3mM and incubated for 1 h or 3 h
to induce oxidative stress.
2.5. Internalization of TAT-Bcp1 in H9c2 Cells. H9c2 cells
were seeded in 6-well plates at a density of 2 × 105 cells/well
in 2mL of medium, and then TAT-Bcp1 (0.5−10𝜇M) was
added to the cells and incubated for different times (1 h, 4 h,
16 h, and 24 h). As a control, the cells were incubated with
buffer diluted in medium. The cells were then detached with
trypsin-EDTA, harvested by centrifugation, and washed with
PBS. The cells were lysed on ice for 20min in 0.5% Triton
X-100 in PBS containing a complete EDTA-free protease
inhibitor cocktail. After centrifugation at 1,500×g for 10min
at 4∘C, the supernatant representing the cytoplasmic fraction
was collected and quantified by the Bradford method [21]
using Bio-Rad Protein Assay Reagent (Bio-Rad, Germany).
Fifty micrograms of cytoplasmic proteins was separated by
SDS-PAGE on a gel containing 15% polyacrylamide and
then examined by western blot analysis using a horseradish
peroxidase- (HRP-) conjugated anti-5X His tag antibody
(mAb) (Qiagen) diluted 1 : 2,000 in blocking buffer. Chemi-
luminescent detection was performed according to the man-
ufacturer’s recommendations (Immobilon Western Chemi-
luminescent HRP Substrate, Millipore, MA, USA) using the
Chemidoc system (Bio-Rad). The quantitative analysis was
performed using Quantity One software.
2.6. Cell Viability Assay. Cell viability was evaluated using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay [22]. H9c2 cells were seeded in 96-
well plates at a density of 3.5 × 103 cells/well in 0.1mL of
DMEM. After 24 h, the cells were incubated with 10 𝜇M
TAT-Bcp1 for different times (1 h, 4 h, 16 h, 24 h, 48 h, and
72 h). As a control, the cells were incubated with buffer
diluted in medium. The MTT solution (Sigma-Aldrich,
Milano, Italy) was added at 0.5mgmL−1 in DMEM without
phenol red (0.1mL/well). After a 4 h incubation at 37∘C, the
formazan salts were solubilized in 0.04M HCl in anhydrous
isopropanol and cell viability was evaluated bymeasuring the
𝐴
570 nm using an automatic plate reader spectrophotometer
(VICTOR3 Multilabel Counter, Perkin Elmer, Shelton,
CA, USA). Cell survival was expressed as the means of the
percentage values compared to the control. Each sample was
analysed in triplicate and the assay has been repeated at least
three times.
2.7. Measurement of the H2O2 Content. TheH2O2 levels were
determined using a Fluorescent Peroxide Sensor (MAK164
Sigma-Aldrich), which generates a fluorescent product pro-
portional to the H
2
O
2
content following a reaction with
H
2
O
2
.
The intracellular H
2
O
2
levels were measured under (1)
physiological and (2) stressed conditions.
(1) H9c2 cells were pretreated or with or without increas-
ing concentrations of TAT-Bcp1 (1–20𝜇M) for 60min
at 37∘C. Next, the cells were washed twice in PBS and
lysed as reported above.Then, the samples were incu-
bated with the Fluorescent Peroxide Sensor diluted
in working solution according to the manufacturer’s
instructions and incubated for 30min at 37∘C. The
fluorescence intensity was measured using a multi-
mode reader synergy HT calibrated for excitation at
490 nm and emission at 525 nm.
(2) H9c2 cells were pretreated with TAT-Bcp1 (10 𝜇M for
16 h) and then stressed with 0.3mM H
2
O
2
for 30 or
60min at 37∘C.The cells were then washed and lysed,
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and finally the H
2
O
2
levels were measured using the
fluorescence assay described above. Every experiment
included four replicates.
2.8. Cell Apoptosis. H9c2 cells were seeded in 6-well plates at
a density of 1.5 × 105 cells/well in 2mL of DMEM and grown
to nearly 70% confluence.The cells were then incubated with
10 𝜇M TAT-Bcp1 for different times (1 h, 4 h, 16 h, and 24 h)
before treatment with H
2
O
2
(0.3mM for 1 and 3 h).
2.9. EB and AO Staining Assay. Apoptotic cells were detected
by ethidium bromide (EB) and Acridine Orange (AO) stain-
ing of the nuclei [23]. AO permeates all cells and stains the
nuclei green, whereas EB is only incorporated in apoptotic
cells, staining the nuclei red.
The cells were detached with trypsin-EDTA, washed with
ice-cold PBS, resuspended in 50 𝜇L of PBS containing a
5 𝜇gmL−1 EB/AO dye mixture, and incubated at 37∘C for
20min.The stained cells were visualized under a fluorescence
microscope (Nikon Eclipse E-100). Images were taken at 100x
magnification. Both the apoptotic (red) and live (green) cells
in each sample were counted in five microscopic fields.
2.10. PARP-1 Cleavage. Nuclear extracts were prepared by de-
taching the cells with trypsin-EDTA, incubating them on
ice for 10min in 10mM Hepes, pH 8.0, containing 10mM
KCl, 1.5mMMgCl
2
, 0.5mMDTT, and a complete EDTA-free
protease inhibitor cocktail (Roche), lysing them by adding
0.1%NP-40, and centrifuging the lysates at 1,500×g for 10min
at 4∘C. The pellet was dissolved in RIPA buffer (50mM
Tris-HCl, pH 8.0, 150mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, and 0.1% SDS) containing a protease inhibitor
cocktail and incubated on ice for 30min. After centrifu-
gation at 1,500×g for 30min at 4∘C, the nuclear protein
concentration was measured using the Bradford method
[21], and 30 𝜇g of the protein extracts was separated by 10%
SDS-PAGE. Western blotting analysis was performed using
the chemiluminescent method and the following antibodies:
poly(ADP-ribose) polymerase-1 (PARP-1)mAb (C2-10, Santa
Cruz, CA) diluted 1 : 2,000 in blocking buffer (5% BSA in TBS
buffer containing 0.1% v/v Tween 20) or the B23mAb (Sigma-
Aldrich, St. Louis, USA; 1 : 2,000 dilution) as loading control
for the nuclear proteins. AnHRP-conjugated goat anti-mouse
IgG was used for detection (Pierce, Rockford, IL, USA).
2.11. Statistical Analysis. The data for the cell viability and
cell apoptosis assays are presented as the means ± SD of at
least three repeats. Statistical analysis was performed using a
two-tailed Student’s t-test. A 𝑝 value < 0.05 was defined as
indicating a statistically significant difference.
3. Results
3.1. Sequence Alignment of Bcp1 with Prx Orthologues. The
CLUSTAL multiple alignment of Bcp1 versus human Prxs
(hPrx1 and hPrx2) [24], Prx (Dot5p) from Saccharomyces
cerevisiae [25], and prokaryotic Prxs belonging to Vibrio
vulnificus (VvPrx1 and VvPrx2) [9] was performed using
MUSCLE (3.8). As shown in Figure 1, Bcp1 has the highest
percent identity with Dot5p and hPrxI of 35% and 33%,
respectively. The first similarly to Bcp1 is the atypical 2-Cys
Prxs, and the two enzymes are characterized by a CxxxxxC
motif, in which the two cysteine residues are the CP and CR,
respectively [4, 25], but it does not retain the sensitivitymotifs
to overoxidation (GGLG and YT at C-terminus). The latter,
which belongs to the typical 2-Cys Prxs, has a similar percent
identity but has the sensitivitymotif that renders it susceptible
to overoxidation. On the other hand, VvPrx1 and VvPrx2,
which belong to the prokaryotic domain, show lower identity
with Bcp1 (25% and 27%, resp.), and only the first presents the
overoxidation motif. This analysis suggests that prokaryotic
Bcp1 could be a robust peroxiredoxin that also functions in
all eukaryotic environments.
3.2. Bcp1 Peroxidase Activity. Bcp1 was expressed in E. coli,
purified [12], and the peroxidase activity was successively
determined at 37∘C and at different pH values using the
DTT assay reported in the MM to detect Bcp1 peroxidase
activity under the typical temperature and pH conditions
of eukaryotic cells. Our results showed that Bcp1 was able
to remove 100% of H
2
O
2
at 37∘C (data not shown) and
that the optimal peroxidase activity was achieved at pH 7.0
(Figure 2(a)). In addition, pH stability was determined by
incubating Bcp1 at different pH values (5.5–7.0) for various
times and then measuring H
2
O
2
removal (Figure 2(b)). After
16 h incubation at pH 7.0, Bcp1 retained 100% of its initial
activity, while at pH 6.5, 6.0, and 5.5, the enzyme maintained
60%, 70%, and 33% of its initial activity, respectively. At pH
5.5, the relative Bcp1 activity decreased to 47% of the starting
value after two hours of incubation.
It was previously described that Bcp1 is coupled with an
unusual redox system composed of SsTrxR with SsPDO for
recycling [4]. We monitored the Bcp1 peroxidase reaction
using the yeast Trx system (yTrxR/yTrx) and NADPH as an
electron source to verify that Bcp1 activity was supported
by eukaryotic disulfide reductase system. This system was
successfully used to measure the peroxidase activity of hPrx1
and hPrx2 [18, 24]. Therefore, we expressed and purified
yTrxR and yTrx from E. coli and determined their reducing
activities, as reported in the MM (data not shown). Initially,
Bcp1 peroxidase activity was determined by measuring the
consumption of NADPH, which was revealed by a decrease
in absorbance at 340 nm (Figure 3(a)); then, different con-
centrations of yTrx were used to determine the kinetic
parameters (Figure 3(b)). Our results showed that Bcp1 had a
𝐾
𝑚
value of 54.9 𝜇M using this heterologous system.
3.3. Generation of a Pure TAT-Bcp1 Fusion Protein. Previous
studies showed that when theHIVTransactivating Transduc-
tion (TAT) domain, a short basic polypeptide of 11 amino
acids residues, was fused with a target protein it confers the
ability to penetrate across the lipid bilayer of the cells due to
the strong binding of the positively charged TAT domain to
the negative charges on the cell surface [17].
We generated the TAT-Bcp1 fusion protein by cloning
bcp1 into pTAT2.2 vector to allow Bcp1 internalization into
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Dot5p MGEALRRSTRIAISKRMLEEEESKLAPISTPEVPKKKIKTGPKHNANQAVVQEANRSSDV
SsBcp1 ------------------------------------------------------------
VvPrx1 ------------------------------------------------------------
VvPrx2 ------------------------------------------------------------
hPrx1 ---------------------------------------------------------MSS
hPrx2 ---------------------------------------------------------MAS
Dot5p NELEIGDPIPDLSLLNEDNDS-----ISLKKITENNRVVVFFVYPRASTPGCTRQACGFR
SsBcp1 -MVKVGDKAPLFEGIADNGEK-----ISLSDYIGKHNIVLYF-YPKDDTPG TREACAFR
VvPrx1 ---MINTTIKPFSATAYK-DGKFVD-ITEQDV-LGKWSVFFF-YPADFTFV PTELGDLA
VvPrx2 -MVLVGRQAPDFTAAAVLGNGEIVDNFNFAEFTKGKKAVVFF-YPLDFTFV PSELIAFD
hPrx1 GNAKIGHPAPNFKATAVMPDGQFKD-ISLSDY-KGKYVVFFF-YPLDFTFV PTEIIAFS
hPrx2 GNARIGKPAPDFKATAVV-DGAFKE-VKLSDY-KGKYVVLFF-YPLDFTFV PTEIIAFS
: . : : .. . : . : . : :
Dot5p DNYQELKKYAA-VFGLSADSVTSQKKFQSK-------QNLPYHLLSDPKREFIGLLGAKK
SsBcp1 DNWDLLKDYDVVVIGVSSDDINSHKRFKEK-------YKLPFILVSDPDKKIRELYGAK-
VvPrx1 DHYEELQSRGVEVFSVSTDTHFTHKAWHDS---SDTIGKIKYFMVGDQTGNITNNFGVMR
VvPrx2 NRYEDFKAKGVEVIGVSIDSQFSHNAWRNTPVENGGIGQVKYPLIADVKHEICQAYDVEH
hPrx1 DRAEEFKKLNCQVIGASVDSHFCHLAWVNTPKKQGGLGPMNIPLVSDPKRTIAQDYGVLK
hPrx2 NRAEDFRKLGCEVLGVSVDSQFTHLAWINTPRKEGGLGPLNIPLLADVTRRLSEDYGVLK
: . : : . : . : : . . : : : . : . .
Dot5p TPLSGSIRSHFIFVDGKLKFKRVKISPEVSVNDAKKEVLEVAEKFKEE------------
SsBcp1 ---GFILPARITFVIDKKGIIRHIYNSQMNPANHVNEALKALKQIKEEEIS---------
VvPrx1 PGQGLADRA--TFVIDPQGVIQAVEITAEGIGRDAEDLLRKIKAAQYVAAHPGEVCPAKW
VvPrx2 PEAGVAFRG--SFLIDEDGLVRHQVVNDLPLGRNIDEMLRMVDALNFHQKH-GEVCPAQW
hPrx1 ADEGISFRG--LFIIDDKGILRQITVNDLPVGRSVDETLRLVQAFQFTDKH-GEVCPAGW
hPrx2 TDEGIAYRG--LFIIDGKGVLRQITVNDLPVGRSVDEALRLVQAFQYTDEH-GEVCPAGW
. . : . . . . : . :
Dot5p --------------------------- 35%
SsBcp1 ---------------------------
VvPrx1 KEGEQTLAPSLDLVGKI---------- 25%
VvPrx2 EEGKAGMDASPQGVAAFLSEHAADLKK 27%
hPrx1 KPGSDTIKPDVQKSKEYFSKQK-----
hPrx2 KPGSDTIKPNVDDSKEYFSKHN----- 30%
33%
C
C
C
C
C
∗ ∗ ∗∗ ∗ ∗
∗ ∗ ∗∗
∗ ∗
Figure 1: Alignment of SsBcp1 with the Prx orthologues. The multiple sequence alignment of S. solfataricus Bcp1 (AAK42253), H. sapiens
hPrx1 (BAG70076) and hPrx2 (AAH39428), S. cerevisiaeDot5p (DAA08535), andV. vulnificus VvPrx1 (ADV88988) andVvPrx2 (ADV87477)
was performed using the MUSCLE algorithm. Identical and similar amino acids are marked with asterisks and points, respectively. The
peroxidatic cysteines are indicated in white and the resolving cysteines are underlined; the motifs for the sensitive Prxs are boxed andmarked
with arrows.
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Figure 2: Analysis of the pH optimum and pH stability of Bcp1. H
2
O
2
removal was measured using the ferrothiocyanate method in the
presence of DTT as the electron donor at 37∘C. (a) The optimum pH was measured in buffers within the range pH 5.5–7.5. (b) pH stability
was determined at 37∘C by incubating Bcp1 in different buffers, pH 5.5 (X), pH 6.0 (◼), pH 6.5 (󳵳), and pH 7.0 (e), for the following times:
30min, 1 h, 2 h, 4 h, and 16 h.
the cell. The recombinant plasmid, pTAT2.2-Bcp1 (Figure
S1A), was used to produce a soluble fusion protein with the
TAT domain at the N-terminus and a His tag at the C-
terminus. TAT-Bcp1 was purified by heat-treatment followed
by IMAC chromatography using the conditions described
for Bcp1 [4]. The SDS-PAGE analysis (Figure S1B) revealed
a single band of ∼19 kDa, which agreed with the predicted
molecular weight of 20.229 kDa.
The purified enzyme was functionally characterized. The
DTT assay was performed and the results revealed that,
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Figure 3: Bcp1 peroxidase activity is dependent on yTrxR/yTrx. The activity was measured by the consumption of NADPH via a decrease in
absorbance at 340 nm. (a) Time course of NADPH oxidation: the peroxidase activity of Bcp1 (3.5 𝜇M) was measured at 30∘C in presence of
yTrxR (0.1 𝜇M) and yTrx (0.1mM). The reaction was started by adding 0.2mM H
2
O
2
. (b) Michaelis-Menten plot of Bcp1 using yTrx as the
substrate.
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Figure 4: Transduction of TAT-Bcp1 in H9c2 cells. A western blot analysis of the cytoplasmic extracts was performed to detect TAT-Bcp1
in the H9c2 cells; the cytoplasmic proteins were analysed with a penta-His HRP-conjugated mAb. Actin was used as the cytoplasmic marker
(lower panels). (a) H9c2 cells were cultured in growth medium (lane 1) and incubated with 0.5 𝜇M (lane 2), 5 𝜇M (lane 3), and 10𝜇M (lane 4)
TAT-Bcp1 for 1 h. Purified TAT-Bcp1 was loaded as reference (lane 6). (b) H9c2 cells were cultured in growth medium (lane 6) and incubated
with TAT-Bcp1 (10𝜇M) for 1 h (lane 7), 4 h (lane 8), 16 h (lane 9), and 24 h (lane 10). Increasing amounts of purified TAT-Bcp1 were loaded to
construct a calibration curve to determine the intracellular TAT-Bcp1 levels: 25 ng (lane 1), 50 ng (lane 2), 75 ng (lane 3), and 100 ng (lane 4).
similar to Bcp1, TAT-Bcp1 was able to reduce all of the H
2
O
2
under the same pH and temperature conditions (data not
shown).
3.4. TAT-Bcp1 Internalization into H9c2 Cells. It is widely re-
ported that H
2
O
2
contributes to the initiation and the pro-
gression of cardiovascular diseases, including atherosclerosis
[26]. We chose H9c2 rat cardiomyoblasts, nonmalignant
cardiac-like cells that are commonly used to study the molec-
ular response to oxidative damage [27], as a model system to
evaluate the effects of TAT-Bcp1 on cells undergoing oxidative
stress. First, we established the optimal conditions for TAT-
Bcp1 internalization. Therefore, we cultured the H9c2 cells
and incubated them with different amounts (0–10 𝜇M) of the
fusion protein for 1 h. As shown in Figure 4(a), the western
blot analysis of the cytoplasmic extracts showed that 10 𝜇M
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Figure 5: Effect of TAT-Bcp1 onH9c2 cell viability. Cell viability was
determined using the MTT assay. The cells were cultured in normal
growthmedium and then treatedwith TAT-Bcp1 (10𝜇M) for 1 h, 4 h,
16 h, and 24 h. Cell viability was evaluated by measuring the𝐴
570 nm;
the data are expressed as the mean percentages ± SD. compared to
the control. ∗𝑝 < 0.001; the results were derived from four replicates
of a representative experiment.
TAT-Bcp1 was the optimal concentration for internalization
into H9c2 cells. Afterwards, TAT-Bcp1 internalization was
analysed at 1 h, 4 h, 16 h, and 24 h (Figure 4(b)). The fusion
protein was detected in the cells after 1 h (lane 7, upper
panel), whereas 16%, 49%, and 69% decreases were observed
after 4 h, 16 h, and 24 h, respectively (lanes 8–10, upper
panel). This effect could be related to the common protein
turnover mechanism because a constant amount of TAT-
Bcp1 was present in the supernatants at the different times
(Figure S2, lanes 6–9 (see Supplementary Material available
online at http://dx.doi.org/10.1155/2016/7424870)). No band
was detected when buffer alone was diluted into the culture
medium (Figure 4(a), lane 1, and Figure 4(b), lane 6, upper
panels; Figure S2, lane 5).These data indicate that TAT-Bcp1 is
optimally delivered into the cells at 10𝜇Mand is stable within
4 h after administration.
3.5. The Effect of TAT-Bcp1 on Cell Viability. The MTT as-
say was performed to evaluate whether TAT-Bcp1 had any
cytotoxic effect on the H9c2 cells. The cells were cultured in
growthmedium and treatedwith 10 𝜇MTAT-Bcp1 for 1 h, 4 h,
16 h, and 24 h (Figure 5). After a 1 h incubation, cell growth
was 96.6 ± 1.2%, whereas after 16 h and 24 h, the cell survival
was slightly but significantly higher than 100% (106.1 ± 3.2
and 111.5 ± 1.4%, resp.; 𝑝 value < 0.01), showing that TAT-
Bcp1 was not cytotoxic to H9c2 cells.The incubation was also
extended to 72 h (Figure S3), and the results showed that 95%
and 91% of the cells survived at 48 h and 72 h, respectively,
confirming the data described above.
3.6. TAT-Bcp1 Affects the H2O2 Concentrations in H9c2 Cells
under Physiological or Stressed Conditions. The endogenous
H
2
O
2
content was measured in lysates of H9c2 cells that had
been treated with increasing concentrations of TAT-Bcp1 and
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Figure 6: Effect of TAT-Bcp1 on H
2
O
2
levels in H9c2 cells. (a)
Dose-dependent effect of TAT-Bcp1 (1–20𝜇M) on the H
2
O
2
content
in H9c2 cells grown under physiological conditions. (b) Effect of
the TAT-Bcp1 pretreatment on unstressed and H
2
O
2
-stressed cells.
Unstressed cells (dark bars); H
2
O
2
-stressed cells (light bars).
were or were not subjected to oxidative stress to establish the
effect of TAT-Bcp1 on the H
2
O
2
content in H9c2 cells.
In the first case, the H
2
O
2
levels in H9c2 cell lysates
were determined after incubation with increasing amounts
(1 to 20𝜇M) of TAT-Bcp1 for 1 h at 37∘C. The H
2
O
2
levels in
the lysates were determined using the Fluorescent Peroxide
Sensor (see Section 2.7). As shown in Figure 6(a), a decrease
of H
2
O
2
content was detected in a TAT-Bcp1 dose-dependent
manner, indicating that the proteinwas able to cooperatewith
the endogenous reducing systems for H
2
O
2
removal.
In the latter case, we investigated the antioxidant activity
of TAT-Bcp1 by measuring the H
2
O
2
levels in cells subjected
to oxidative stress. As shown in Figure 6(b), the H
2
O
2
levels
in the TAT-Bcp1 pretreated, stressed cells (see methods) were
significantly reduced compared to the untreated samples.
Taken together, these results indicate that TAT-Bcp1 reduces
the H
2
O
2
content in H9c2 cells under both physiological and
oxidative stress conditions.
3.7. TAT-Bcp1 Protects H9c2 Cardiomyoblasts from H2O2-
Induced Cell Apoptosis. The H9c2 cells were pretreated with
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Figure 7: Effect of TAT-Bcp1 on cell apoptosis. Cell apoptosis
was evaluated using EB and AO staining. H9c2 cells were treated
with TAT-Bcp1 (10𝜇M) for different times (1 h, 4 h, 16 h, and
24 h) and then subjected to oxidative stress with 0.3mM H
2
O
2
for 1 h. (a) Representative images of the control cells (untreated
with TAT-Bcp1) under growth and stress conditions showing both
apoptotic (red) and live (green) cells. (b) The graph shows the
mean percentages ± SD. of apoptotic cells. The grey and black bars
represent the unstressed and stressed cells, respectively. #𝑝 ≪ 0.01
versus the Ctrl growth condition; ∗𝑝 ≪ 0.001 versus the Ctrl stress
condition.
10 𝜇M TAT-Bcp1 for different incubation times (1–24 h) and
then exposed to 0.3mM H
2
O
2
for 1 h to study the effect of
TAT-Bcp1 on H
2
O
2
-induced apoptosis. Cell apoptosis was
analysed by EB and AO staining (Figure 7(a)).
A significant increase in the number of apoptotic cells
was observed following the induction of oxidative stress;
the percentage of H
2
O
2
-treated apoptotic cells was approx-
imately 3-fold higher (45.3 ± 2.3%) (Figure 7(b), Ctrl black
bar) than the unstressed cells (15.7 ± 4.1%) (Figure 7(b),
Ctrl grey bar). Pretreatment with TAT-Bcp1 produced a
protective effect against H
2
O
2
-induced cell apoptosis in a
time-dependent manner. Indeed, after 1 h and 4 h incubation
with TAT-Bcp1, the percentage of apoptotic cells was 41.6 ±
4.3% and 42 ± 7,8%, respectively, similar to that observed
under stress conditions. In contrast, at 16 h and 24 h, the
percentage of apoptotic cells was significantly reduced 1.6-
fold (28.7 ± 4.2% and 26.6 ± 5.9%, resp.). Furthermore,
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Figure 8: PARP-1 cleavage analysis. A western blot analysis of
PARP-1 was performed using nuclear extracts. H9c2 cells were
cultured under growth (lane 1) and stress conditions with 0.3mM
H
2
O
2
for 3 h (lane 2) or pretreated with TAT-Bcp1 (10𝜇M) for
different times, 1 h (lane 3), 4 h (lane 4), 16 h (lane 5), and 24 h
(lane 6), before oxidative stress was induced (a). B23 was used as
the nuclear marker (b). Both the 116 kDa full-length fragment and
89 kDa cleaved fragment are shown.
the administration of TAT-Bcp1 to the unstressed cells did
not induce any increase in cell apoptosis (Figure 7(b), grey
bars), consistent with the results obtained from the MTT
assay.
PARP-1 cleavage was examined by a western blot analysis
of nuclear extracts to confirm the effect of TAT-Bcp1 on
H
2
O
2
-induced cell apoptosis (Figure 8). Typical PARP-1
cleavage was detected under the stress conditions induced
by incubating the cells with 0.3mM H
2
O
2
for 3 h (Figure 8,
lane 2), whereas pretreatmentwith 10𝜇MTAT-Bcp1 inhibited
PARP-1 cleavage, showing a pattern that was similar to the
control (Figure 8, lanes 3–6). In particular, under stress
conditions, the level of the full-length fragment showed a 25%
decrease compared to the control, whereas, after the TAT-
Bcp1 pretreatment, the level of the full-length fragment level
was 94% after 1 h and 100% after 4, 16, and 24 h, showing a
cellular response that was comparable among the different
pretreatment times.
In accord with the data from the EB and AO assays, the
PARP-1 cleavage analysis confirms the antiapoptotic effect of
TAT-Bcp1 in H
2
O
2
-stressed cells.
4. Discussion
Prxs have recently received more attention because they are
very efficient at removing low concentrations of H
2
O
2
due
to both their high abundance and low 𝐾
𝑚
(∼20𝜇M) [28,
29]. Prxs, which are usually expressed in different isoforms,
are evolutionarily conserved from the Archaea, such as S.
solfataricus, in which four enzymes have been extensively
characterized, to man, in which six isoenzymes with different
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roles and subcellular localizations have been identified. The
ubiquity of Prxs and their homology conserved among the
different phylogenetic domains show the important roles
of these enzymes in addition to their peroxidase activities
[30]. Although they retained the Trx fold that characterizes
this family and peroxidase activity [2], these enzymes have
implemented their functions by inserting a sensitivity motif
in their structure to achieve fine tuning of the peroxide
levels and play a regulatory role in cells. Growing evidence
suggests both the unquestionable involvement of Prxs in
the oxidative stress response and their role in regulating the
intracellular H
2
O
2
levels, which are responsible for cell pro-
liferation, angiogenesis, and apoptosis [31–33]. Furthermore,
it was shown that the sensitivity motif that promotes the
overoxidation of Prx evolved independently in eukaryotic
and prokaryotic species [34].
Our studies have focused on the antioxidant activity of
a robust Prx to develop new antioxidant drugs; we chose
prokaryotic Prx, Bcp1, from S. solfataricus that lacks the
sensitivity motif and has a higher robustness compared to
its eukaryotic counterparts. Starting from these differences,
we first assessed whether Bcp1 exhibited peroxidase activity
under conditions that are typical of mammalian cells and in
the presence of the eukaryotic recycling system yTrxR/yTrx.
Our results showed that the enzyme can function at 37∘C and
pH 7.0 and is still stable after 16 h incubation under these
conditions, highlighting the potential use of this enzyme in
biotechnological applications [35]. In contrast to eukaryotic
and bacterial Prxs, Bcp1 has a peculiar recycling system com-
posed of TrxR/PDO [13] instead of the TrxR/Trx reducing
system that is generally used by eukaryotes. Consequently, it
was not obvious whether Bcp1 could interact with yTrx in the
hybrid regenerating system. Our results not only showed that
Bcp1 was effective at reducing the H
2
O
2
levels in the presence
of the yTrxR/yTrx system but also showed that its affinity
with yTrx was comparable to that reported for human Prxs
[18], suggesting a possible activity of Bcp1 in eukaryotic cells.
Based on the in vitro characterization, we analysed the effect
of Bcp1 on H
2
O
2
-induced apoptosis into H9c2 cells, with the
aim of analysing the possible use of the archaeal Prx as an
antioxidant.
We designed the fusion protein TAT-Bcp1 to mediate its
internalization into H9c2 cells and to analyse the effect of
Bcp1 on the cell stress response. TAT-Bcp1 was effectively
detected in the cells at 1 h after administration and gradually
decreased to 70% after 24 h, in agreement with the protein
turnover rates. Furthermore, the protein did not induce any
cytotoxic effects, but it could have a cytoprotective effect, as
shown by the slight but significant increase in cell viability at
16 h and 24 h. The results obtained in this study indicate that
TAT-Bcp1 not only efficiently decreased the H
2
O
2
levels in
H9c2 cells under both physiological and stressed conditions,
showing that the enzyme can use the endogenous recycling
system, but was also able to reduce apoptosis, as shown in
the EB/AO staining assay in Figure 7 and in the PARP-1
cleavage analysis in Figure 8. Together, these results suggest
that the antioxidant activity of TAT-Bcp1 could play a role in
protecting cells from apoptosis.
5. Conclusions
This study is the first report of an archaeal enzyme delivered
into mammalian cultured cells that is able to protect cells
from oxidative stress by reducing both the peroxide levels
inside the cells and the resulting apoptosis. The intrinsic
stability of Bcp1 and its modification, which provides the
ability to penetrate cells, makes TAT-Bcp1 a good candidate
to study the effectiveness of scavenging ROS in the cell.
Growing evidence is highlighting the roles of Prxs in different
diseases, ranging from diabetes to neurological disorders to
cardiovascular diseases; therefore, this work aims to provide
new insights into the possibility of using alternative sources
of antioxidant enzymes, such as those from thermophilic
microorganisms.
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